• Vaccine Name: RABAVERT
• Target Pathogen: Rabies virus
• Target Disease: Rabies
• Manufacturer: Novartis Vaccines and Diagnostics
• Vaccine Ontology ID: VO_0000094
• Type: Inactivated or "killed" vaccine
• Status: Licensed
• Location Licensed: USA (License #1754), Canada
• Host Species for Licensed Use: None
• Preparation: The strain Flury LEP was obtained from American Type Culture Collection as the 59th egg passage. The growth medium for propagation of the virus is a synthetic cell culture medium with the addition of human albumin, polygeline (processed bovine gelatin) and antibiotics. The virus is inactivated with beta-propiolactone, and further processed by zonal centrifugation in a sucrose density-gradient. The vaccine is lyophilized after addition of a stabilizer solution, which consists of buffered polygeline and potassium glutamate (Rabavert)
• Immunization Route: Intramuscular injection (i.m.)
• Storage: RabAvert should be stored protected from light at 2°C to 8°C (36°F to 46°F) (Rabavert).
• Contraindication: There is no contraindication to post-exposure immunization. Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g. hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion should not be immunized with this vaccine (Rabavert).
• Description: The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation

Human Response

• Immune Response: When administered according to the recommended immunization schedule (days 0, 7, 21), 100% of subjects attained a protective titer (Rabavert).
• Side Effects: The most common side effects reported are: injection site reactions (redness, itching, and swelling), fever, and swollen lymph nodes (Rabavert).